ruxolitinib,MaaT013
novartis,incyte,MaaT Pharma
['ruxolitinib', 'rux,(-crux),(-trux)', 'rux,(-crux),(-trux),(-deruxtecan)']
congress #ash22 | presents data on maat013 in the eap. n = 81 pts with sr/sd gi-agvhd. d28 gi orr = 56% &amp; os was 51% at 6 months. agvhd response was improved in 31 patients previously treated with ruxo as 2nd line &amp; maat013 as 3rd line #gvhd #bmtsm 
A global online platform providing latest treatment options and medical information in graft-versus-host disease (GvHD). #gvhd